NNZ-2591
Phelan-McDermid Syndrome
Key Facts
About Neuren Pharmaceuticals
Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.
View full company profile